Lucein Diagnostic

Lucence is a precision oncology company specializing in ultra-sensitive liquid biopsy tests for cancer screening and treatment selection. The company's flagship platform, LiquidHALLMARK, utilizes proprietary AmpliMARK technology to sequence circulating tumor DNA and RNA with high sensitivity, covering 80 genes and multiple cancer types. Lucence provides comprehensive genomic profiling to help clinicians identify actionable mutations and monitor treatment response in late-stage cancer patients. Headquartered in Palo Alto and Singapore, the company operates CLIA-certified and CAP-accredited laboratories to serve a global market, including recent expansion into multi-cancer early detection (MCED) with its LucenceINSIGHT test.